Thursday, January 26, 2023
- Advertisment -
HomeNewsBusinessAs a result of clinical advancements, Azafaros strengthens its medical and scientific...

As a result of clinical advancements, Azafaros strengthens its medical and scientific management team

Two important appointments were made today by Azafaros B.V., further bolstering its senior management group. Dr. Kyle Landskroner has been elevated to Chief Scientific Officer, and Dr. Christian Freitag joins the organisation as Chief Medical Officer. They will aid in the advancement of Azafaros’ pipeline and the transition of the company’s main programme, AZ-3102, into late-stage clinical evaluation thanks to their extensive expertise in clinical and early-stage drug development.

Dr. Freitag was Chief Medical Officer at Dynacure prior to joining Azafaros, where he was in charge of medical and regulatory strategy, as well as clinical development of the lead drug in Myotubular and Centronuclear Myopathies (CNM). Dr. Ruben Giorgino is replaced by Dr. Freitag because he is starting a new career.

A physician named Christian Freitag has over 20 years of expertise in the pharmaceutical sector. He has held leadership positions with firms including Hoffmann La Roche, Shire, and BTG, where he oversaw international clinical development initiatives.

Azafaros’ Chief Medical Officer, Christian Freitag, said: “Joining Azafaros at this moment is incredibly exciting. A couple of the company’s significant initiatives are the execution of the AZ-3102 Phase 2 trial for the treatment of GM2 and Niemann-Pick disease type C, as well as the gathering of very pertinent data on the Natural History of GM1 and GM2 gangliosidosis. In light of the excellent results from the Phase 3 trial, we are also quite motivated to move forward with our planning.

News Summary:

  • As a result of clinical advancements, Azafaros strengthens its medical and scientific management team
  • Check all news and articles from the latest Business news updates.
RELATED ARTICLES

Latest

- Advertisment -